IFNA2 and Cirrhosis: Importantly, administration of a finite course of PEG-IFN-α-2b did not accelerate the disease progression for cirrhosis, which presented as comparable LSM, thickness and length of spleen, as well as diameter of portal vein post PEG-IFN-α-2b therapy.